{
  "resourceType": "Bundle",
  "type": "document",
  "entry": [
    {
      "resource": {
        "resourceType": "Patient",
        "name": [
          {
            "text": "[redacted]"
          }
        ],
        "gender": "female"
      }
    },
    {
      "resource": {
        "resourceType": "Encounter",
        "period": {
          "start": "[redacted]",
          "end": "[redacted]"
        },
        "hospitalization": {
          "admitSource": {
            "text": "Large lobulated multicompartmental supra-sellar mass centered within the hypothalamus/optic chiasm."
          }
        }
      }
    },
    {
      "resource": {
        "resourceType": "Condition",
        "code": {
          "text": "Large lobulated multicompartmental supra-sellar mass centered within the hypothalamus/optic chiasm"
        },
        "subject": {
          "reference": "Patient/[redacted]"
        },
        "onsetString": "[redacted]",
        "abatementString": "[redacted]",
        "note": [
          {
            "text": "The patient, a two-year-old female with a six-week history of macrocephaly and truncal and peripheral ataxia, was admitted to the hospital for further evaluation. An urgent brain MRI demonstrated the presence of a large lobulated multicompartmental supra-sellar mass centered within the hypothalamus/optic chiasm, with extension into the surrounding structures and mass effect on the midbrain and third ventricle causing obstructive hydrocephalus."
          }
        ]
      }
    },
    {
      "resource": {
        "resourceType": "Procedure",
        "code": {
          "text": "Endoscopic biopsy and septostomy, right-sided ventriculoperitoneal (VP) shunt"
        },
        "subject": {
          "reference": "Patient/[redacted]"
        },
        "performedString": "[redacted]",
        "reasonReference": [
          {
            "reference": "Condition/[redacted]"
          }
        ]
      }
    },
    {
      "resource": {
        "resourceType": "DiagnosticReport",
        "code": {
          "text": "Pathology of the lesion"
        },
        "subject": {
          "reference": "Patient/[redacted]"
        },
        "result": [
          {
            "reference": "Observation/[redacted]"
          }
        ]
      }
    },
    {
      "resource": {
        "resourceType": "Observation",
        "code": {
          "text": "Pathology of the lesion"
        },
        "subject": {
          "reference": "Patient/[redacted]"
        },
        "valueString": "Low-grade glioma, BRAF-V600E negative on immunohistochemistry but positive on next-generation sequencing"
      }
    },
    {
      "resource": {
        "resourceType": "MedicationStatement",
        "medicationCodeableConcept": {
          "text": "Vincristine and carboplatin"
        },
        "subject": {
          "reference": "Patient/[redacted]"
        },
        "note": [
          {
            "text": "Started on chemotherapy with vincristine and carboplatin but had rapid tumor progression with worsening hydrocephalus six weeks into chemotherapy."
          }
        ]
      }
    },
    {
      "resource": {
        "resourceType": "Condition",
        "code": {
          "text": "Progressive right-sided hemiparesis, bitemporal hemianopia, central hypothyroidism, and feeding difficulties"
        },
        "subject": {
          "reference": "Patient/[redacted]"
        },
        "note": [
          {
            "text": "Complications developed due to tumor progression, requiring a gastrostomy tube and placement of a second VP shunt."
          }
        ]
      }
    },
    {
      "resource": {
        "resourceType": "MedicationStatement",
        "medicationCodeableConcept": {
          "text": "Dabrafenib"
        },
        "subject": {
          "reference": "Patient/[redacted]"
        },
        "note": [
          {
            "text": "Started on the novel targeted agent dabrafenib. By three months of starting dabrafenib, the size of her tumor decreased by more than 70%, with continued decline until plateauing after two years of therapy."
          }
        ]
      }
    },
    {
      "resource": {
        "resourceType": "Observation",
        "code": {
          "text": "Motor and speech impairments"
        },
        "subject": {
          "reference": "Patient/[redacted]"
        },
        "valueString": "Prior to dabrafenib, the patient had marked motor and speech impairments but is now able to perform all age-appropriate developmental skills independently."
      }
    },
    {
      "resource": {
        "resourceType": "Observation",
        "code": {
          "text": "Feeding"
        },
        "subject": {
          "reference": "Patient/[redacted]"
        },
        "valueString": "No longer requires tube feeding and has been growing well."
      }
    },
    {
      "resource": {
        "resourceType": "Observation",
        "code": {
          "text": "Bitemporal hemianopia"
        },
        "subject": {
          "reference": "Patient/[redacted]"
        },
        "valueString": "Improved markedly."
      }
    },
    {
      "resource": {
        "resourceType": "Observation",
        "code": {
          "text": "Visual acuity"
        },
        "subject": {
          "reference": "Patient/[redacted]"
        },
        "valueString": "Continues to have low but stable visual acuity bilaterally."
      }
    },
    {
      "resource": {
        "resourceType": "ResearchStudy",
        "title": "ORCYD biomarker study",
        "subject": {
          "reference": "Patient/[redacted]"
        },
        "note": [
          {
            "text": "The patient was enrolled in the ORCYD biomarker study to test her plasma and CSF for the presence of the BRAF-V600E mutation and to correlate the assay results with the MRI changes observed while on dabrafenib therapy."
          }
        ]
      }
    },
    {
      "resource": {
        "resourceType": "Observation",
        "code": {
          "text": "BRAF-V600E mutation"
        },
        "subject": {
          "reference": "Patient/[redacted]"
        },
        "valueString": "The BRAF-V600E mutation was not detected in any of the samples from either plasma or CSF."
      }
    },
    {
      "resource": {
        "resourceType": "MedicationStatement",
        "medicationCodeableConcept": {
          "text": "None"
        },
        "subject": {
          "reference": "Patient/[redacted]"
        },
        "note": [
          {
            "text": "Discharge Medications: None."
          }
        ]
      }
    },
    {
      "resource": {
        "resourceType": "CarePlan",
        "subject": {
          "reference": "Patient/[redacted]"
        },
        "note": [
          {
            "text": "The patient will follow up with her oncologist for regular check-ups and monitoring. Future imaging studies will be performed as needed to evaluate the progression of the tumor."
          }
        ]
      }
    }
  ]
}